Arecor Therapeutics has gained9.24% on 17 August 2026, bringing LSE:AREC back into focus among UK-listed healthcare and biotechnology stocks.
Cambridge Cognition Holdings Plc LSE:COG is attracting renewed attention after its shares declined6.06% on August 17, 2026.
GSK PLC shares were1.10% higher at 1,837.50p today, 17 August 2026, according to the market data provided. The gain reflects continued investor confidence in the group's pharmaceutical and vaccines pipeline.
AstraZeneca PLC shares were1.00% higher at 11,574.00p today, 17 August 2026, according to the market data provided. The gain reflects continued investor confidence in the group's broad oncology and biopharmaceutical pipeline.
hVIVO (LSE:HVO) used its 23 July 2026 half-year trading update to reframe a difficult six months as a story about timing rather than lost demand. The headline number was the order book, which the company said had more than doubled to roughly £65m, up …
Inspiration Healthcare (LSE:IHC)'s full-year results for the year to 31 January 2026, published in June 2026, showed aBusinessthat has both grown strongly and sharpened its strategic focus. The AIM-listed medical-technology group reportedRevenueup 24% and used the results to confirm its pivot towards neonatal intensive …
Avacta (LSE:AVCT) Group, the AIM-listed oncology and diagnostics company, secured an important regulatory milestone in June 2026 when the US Food and Drug Administration agreed that a single pivotal clinical trial could be sufficient to support full approval of its lead cancer drug, AVA6000 …
hVIVO (LSE:HVO) used its 23 July 2026 half-year trading update to reframe a difficult six months as a story about timing rather than lost demand. The headline number was the order book, which the company said had more than doubled to roughly £65m, up …
Inspiration Healthcare (LSE:IHC)'s full-year results for the year to 31 January 2026, published in June 2026, showed aBusinessthat has both grown strongly and sharpened its strategic focus. The AIM-listed medical-technology group reportedRevenueup 24% and used the results to confirm its pivot towards neonatal intensive …
For roughly seventy-two hours in early August, the City entertained the idea that Britain's most valuable listed company was about to disappear into the largest pharmaceutical merger in history. The Financial Times reported that AstraZeneca (LSE:AZN) had held talks with New York's Bristol Myers …